ArticlePloS one2011

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.

Tzong-Tyng Hung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.